SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bhag Karamchandani who wrote (712)5/9/1997 3:22:00 PM
From: John Metcalf   of 6136
 
Good points, Bhag. The small float can lead to whipsaws for traders, whether short or long.

As to confirming revenue, is Agouron constrained by FDA in commenting on Viracept? The report I saw of the FDA letter indicated that they were to submit Viracept press releases to FDA for approval 30 days before releasing them to the public. Do you suppose this will mean no public comments on Viracept efficacy or sales?

(Cynical comment: if I were an FDA employee, I would not trade the stock at all, and I would lock the file cabinet every time I went to the washroom -- )
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News